

# Shared and distinct pathways and networks genetically linked to coronary artery disease between human and mouse

## Reviewed Preprint

Revised by authors after peer review.



[About eLife's process](#)

**Reviewed preprint version 2**  
November 2, 2023 (this version)

**Reviewed preprint version 1**  
August 10, 2023

**Posted to bioRxiv**  
June 11, 2023

**Sent for peer review**  
May 25, 2023

**Zeyneb Kurt, Jenny Cheng, Caden N. McQuillen, Zara Saleem, Neil Hsu, Nuoya Jiang, Rio Barrere-Cain, Calvin Pan, Oscar Franzen, Simon Koplev, Susanna Wang, Johan Bjorkegren, Aldons J. Lusis, Montgomery Blencowe** , **Xia Yang** 

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA • Department of Computer and Information Sciences, University of Northumbria, Ellison Pl, Newcastle upon Tyne NE1 8ST, UK • Interdepartmental Program of Molecular, Cellular and Integrative Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA • Department of Medicine, Division of Cardiology, University of California, Los Angeles, 650 Charles E Young Drive South, Los Angeles, CA 90095-1679, USA • Department of Genetics & Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, US • Department of Medicine, (Huddinge), Karolinska Institutet, 141 57 Huddinge, Sweden • Departments of Human Genetics & Microbiology, Immunology, and Molecular Genetics, UCLA, CA 90095, USA • Cardiovascular Research Laboratory, David Geffen School of Medicine, UCLA, CA 90095 • Interdepartmental Program of Bioinformatics, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

 [https://en.wikipedia.org/wiki/Open\\_access](https://en.wikipedia.org/wiki/Open_access)

 Copyright information

## Abstract

## Summary

Mouse models have been used extensively to study human coronary artery disease (CAD) or atherosclerosis and to test therapeutic targets. However, whether mouse and human share similar genetic factors and pathogenic mechanisms of atherosclerosis has not been thoroughly investigated in a data-driven manner. We conducted a cross-species comparison study to better understand atherosclerosis pathogenesis between species by leveraging multiomics data. Specifically, we compared genetically driven and thus CAD-causal gene networks and pathways, by using human GWAS of CAD from the CARDIoGRAMplusC4D consortium and mouse GWAS of atherosclerosis from the Hybrid Mouse Diversity Panel (HMDP) followed by integration with functional multiomics human (STARNET and GTEx) and mouse (HMDP) databases. We found that mouse and human shared >75% of CAD causal pathways. Based on network topology, we then predicted key regulatory genes for both the shared pathways and species-specific pathways, which were further validated through the use of single cell data and the latest CAD GWAS. In sum, our results should serve as a much-needed guidance for which human CAD-causal pathways can or cannot be further evaluated for novel CAD therapies using mouse models.

### eLife assessment

In this **important** study, the authors integrated genetic and genomic datasets from humans and mice to unveil shared networks and pathways associated with coronary artery disease. Their **compelling** analysis led to the identification of new regulatory genes and pathways in vascular tissues and in the liver, allowing for a more in-depth understanding of the pathogenesis of coronary artery disease.

## Introduction

Coronary artery disease (CAD) represents one of the leading causes of mortality worldwide (Tsao et al., 2022 [↗](#)) and is the most common type of heart disease. CAD is primarily caused by atherosclerosis, or the buildup and hardening of plaque in the arteries, and can lead to arrhythmias, heart attack, and heart failure (Momiya et al., 2014 [↗](#)). It is a complex disease that involves numerous genetic and environmental factors, including poor diet, lack of exercise and smoking (McCarthy et al., 2008 [↗](#)). An individual's risk of developing CAD may be reduced by lifestyle changes, medication, or surgery; however, our ability to mitigate CAD from the number one cause of death is still limited (Khera et al., 2016 [↗](#)). Therefore, a more comprehensive understanding of CAD mechanisms will help develop new preventative and therapeutic strategies.

Mouse models have been extensively used to study atherosclerosis mechanisms and to test therapeutic drugs (Von Scheidt et al., 2017 [↗](#); Xiangdong et al., 2011 [↗](#)). There are many advantages to using mouse models, such as low maintenance cost, fast reproduction cycles, and the ability to control the environment and genetically manipulate their genomes. In addition, the mouse genome shares 95% of the protein coding genes with that of humans. However, there are important differences between the two species that make direct translation of findings from mice to humans less straightforward (Vandamme, 2014 [↗](#)). For example, mice tend to develop larger atherosclerotic lesions in the aorta and carotids, whilst in humans the most consequential plaque lesions develop in coronary arteries (Ma et al., 2012 [↗](#)). Because of the extensive use of mouse models in both mechanistic studies and preclinical investigations of therapeutic targets and drugs, a detailed understanding of the shared and distinct molecular mechanisms through a cross-species comparison will have tremendous translational value in cardiovascular research.

Previously, literature-based analyses revealed limited gene-level sharing between species but 70% sharing at the level of molecular pathways without considering the tissue context or gene regulatory networks (Von Scheidt et al., 2017 [↗](#)). As literature-based findings can be biased (Stoeger et al., 2018 [↗](#)), here we conduct a comprehensive data-driven integrative study utilizing the ample multiomics data resources available to allow a tissue-specific, systems-level assessment of the key similarities and differences in CAD mechanisms between mouse and human. For each species, we focus on genetic and functional genomics datasets, including genome-wide association studies (GWAS) which uncover genetic risk loci, tissue-specific transcriptome data that reveal global gene expression and gene-gene coordination patterns, and tissue-specific expression quantitative trait loci (eQTLs) that reflect genetic regulation of gene expression. Instead of focusing on direct intersections of individual risk genes between species, our study builds on the “omnigenic” disease model that emphasizes pathway and gene network perturbations to make mechanistic comparisons between species (Boyle et al., 2017 [↗](#)). Indeed, recent studies support the involvement of tissue-specific pathways and networks in CAD and other complex diseases (Blencowe et al., 2021 [↗](#); Krishnan et al., 2018 [↗](#); Kurt et al., 2018 [↗](#); Zhao et al., 2019a [↗](#); Zhao et al., 2019b [↗](#)) and that cross-species comparison is more informative at the pathway level. Through multiomics integration, our study reveals both shared and species-specific pathways, networks,

and key regulatory genes. Our findings will help inform on when mice models are appropriate for testing different aspects of atherosclerosis and predict how well findings from mice will translate in human studies, ultimately increasing the likelihood of success in the design, development, and testing of new therapeutic agents for CAD.

## Results

### Multomics study design of CAD/Atherosclerosis

To understand the similarities and differences in CAD/atherosclerosis pathways and candidate disease regulatory genes in human and mouse, we used Mergeomics, to integrate multomics data including GWAS signals, tissue-specific eQTLs, and gene networks to predict causal CAD/atherosclerosis subnetworks and their potential regulator genes in each species (**Figure 1**). From the human side, we included CAD GWAS from the Coronary Artery Disease Genome-wide Replication and Meta-Analysis (CARDIoGRAMplusC4D) consortium and transcriptomes and eQTLs from vascular tissues and liver from the GTEx consortium and the STARNET study. From the mouse side, we used atherosclerosis GWAS from the Hybrid Mouse Diversity Panel (HMDP), which is comprised of over 100 inbred strains of mice, with three to four mice per sex (Bennett et al., 2015), and transcriptomes and eQTLs from aorta and liver tissues from the same mouse cohort. We first constructed co-expression networks using gene expression data from vascular and liver tissues from both species and identified co-expression modules (clusters of co-expressed genes). We then mapped the CAD and atherosclerosis GWAS for human and mouse respectively, to genes using vascular and liver eQTLs. We used these mapped genes from GWAS to look for enrichment of gene sets (co-expression modules or canonical pathways), which will drive modules and pathways that are more likely to be causal and perturbed by genetic risk variants. We then identified gene sets that were shared and unique to each species and mapped the CAD/atherosclerosis-associated gene sets onto Bayesian networks constructed from liver and vascular tissues. These networks contain gene-gene regulatory relationships, which allowed us to predict candidate key driver (KD) genes in these CAD/atherosclerosis-associated gene sets that are potentially causal (see Methods for details).

### Construction of tissue-specific co-expression networks

We constructed co-expression networks from transcriptome data of 299 aortic artery, 173 coronary artery, and 175 liver tissue samples from the GTEx study (Lonsdale et al., 2013) for human, and 554 aortas and 508 liver samples of mice from 101 HMDP strains using two network methods, namely, Weighted Gene Co-expression Network Analysis (WGCNA) (Langfelder and Horvath, 2008) and Multiscale Embedded Gene Co-expression Network Analysis (MEGENA) (Song and Zhang, 2015). WGCNA and MEGENA cluster genes into modules based on the co-regulation structure of the genes using hierarchical clustering (details in Methods). Modules from both methods can be reciprocally conserved, however, their compactness and sizes are different, making these two methods complementary allowing for different levels of biological pathways to be captured, as shown in our previous study (Krishnan et al., 2018).

From the human datasets, we identified 36 co-expression modules in the aortic artery, 21 modules in the coronary artery, and 33 liver modules using WGCNA, whereas with MEGENA we obtained 159, 168, and 168 modules, respectively. For mouse, we identified 52 aorta co-expression modules and 55 liver modules using WGCNA, and 207 aorta and 190 liver modules using MEGENA (**Suppl Table S1**). We pooled these co-expression modules along with 1823 canonical biological pathways from the Molecular Signatures Database (MSigDB) (Subramanian et al., 2005) to identify potential causal CAD/atherosclerosis processes in the next step using the Marker Set Enrichment Analysis (MSEA) function of Mergeomics. Here, co-expression modules represent functionally related genes defined by data-driven analysis, whereas MsigDB pathways capture functionally




Figure 1

Overview of Study.

related genes through knowledge-driven categorization. They are complementary approaches to define genes sets containing functionally coherent genes, which can be combined to capture a potentially broader array of biology.

## Biological pathways and co-expression modules that exhibit genetic association with CAD

Canonical biological pathways and co-expression modules from both species were pooled together, where each gene set (a pathway or module) contains functionally associated genes. We then mapped the GWAS data, which contains the potential causal signals, with the gene sets through species- and tissue-specific eQTLs to identify potential causal gene sets for CAD/atherosclerosis in each species and tissue. Instead of using only the top individual genome-wide significant signals in CAD GWAS, we used the whole spectrum of GWAS single nucleotide polymorphisms (SNPs) and their associated p-values, which allowed us to consider moderate and subtle signals in addition to strong ones. GWAS SNPs were then mapped to genes through species- and tissue-specific eQTLs which represent the functional association between genes and expression single nucleotide polymorphisms (eSNPs) examined in GWAS. For each gene set among the pooled pathways and modules, we mapped the member genes to eSNPs through vascular (aorta in mouse, aorta and coronary arteries in human) or non-vascular tissue (liver in both species) eQTLs by matching the tissue type between eQTLs and co-expression modules. Then, we used the Marker Set Enrichment Analysis (MSEA) procedure from our Mergeomics tool (Ding et al., 2021 [DOI](#); Shu et al., 2016 [DOI](#)) to test whether an eSNP set, which was mapped from a given gene set, is enriched for stronger disease GWAS signals, based on GWAS *P* value scores, compared to eSNP sets from random groups of genes (see Methods).

Among the 1823 canonical pathways and 1089 coexpression modules (643 from vascular tissue, and 446 from non-vascular tissue from both species; **Suppl Table S1**), we found that human CAD GWAS signals from CARDIoGRAMplusC4D were significantly enriched in 47 pathways and 64 vascular tissue co-expression modules informed by vascular tissue eQTLs, whereas 59 pathways and 60 non-vascular (liver) modules were identified as CAD-associated by liver eQTLs (**Suppl Table S2**). Mouse atherosclerosis GWAS signals from HMDP were significantly enriched in 68 pathways and 81 vascular tissue modules through the aortic eQTLs, and 37 pathways and 49 liver modules through liver eQTLs. Some of the CAD-associated pathways or modules share their member genes and correspond to similar biological processes, thereby creating redundancies. To reduce redundancy, we combined significantly overlapping gene sets ( $p < 0.05$ ,  $> 33\%$  gene overlap; see Methods) into “supersets”, yielding 73 and 80 supersets from human and mouse based on vascular tissue analysis, and 74 and 60 supersets from human and mouse based on liver analysis, respectively. Hence, each superset corresponds to one or more CAD/atherosclerosis-associated gene set (see Methods). These merged nonredundant supersets were found to retain enrichment for strong CAD or atherosclerosis-related genetic signals (**Suppl Table S3**).

## Shared pathways and co-expression modules between human and mouse

We compared the CAD/atherosclerosis-associated supersets between mouse and human in each tissue separately. In addition to directly matching the pathways or modules by name or annotation, we also checked the overlap between the member genes of the supersets from both species. A two-sided Jaccard index overlap  $> 50\%$  or a one-sided overlap  $> 90\%$  was accepted as a match between species (see Methods). Since a superset that was found as CAD-associated in one of the species may cover  $> 90\%$  of the genes in more than one superset found in the other species, the number of the shared supersets from each of the species can differ.

Between vascular and liver tissues, we observed shared CAD pathways between tissues and species (**Figure 2**). These include well known signals in atherosclerosis development including metabolism of lipids, lipoproteins, and proteins, extracellular matrix (ECM) organization, platelet activation/signaling/aggregation pathways, TCA cycle, and MAPK signaling.

In the vascular tissue-driven analysis, 53 of the 73 human supersets (73%) and 60 of the 80 mouse supersets (75%) were found to be matched or preserved between species (**Suppl Table S3, Figure 2**). The shared pathways in vascular tissues include those less known for their role in the vasculature including gluconeogenesis, RXR/VDR pathway, and branched chain amino acid (BCAA) catabolism. At the same time, we uncovered some more common terms such as cell cycle, vascular smooth muscle contractions, and metabolism of lipids and lipoproteins (**Figure 2B**).

In the liver-based analysis, 56 of the 74 human supersets (76%) and 51 of the 60 mouse supersets (85%) were preserved between species (**Suppl Table S3, Figure 2C**). The shared pathways in the liver include well characterized terms such fatty acid metabolism, Jak-STAT, PPAR signaling, circadian rhythm, and immune related signals (**Figure 2D**).


### Species-specific CAD-associated mechanisms

We also identified species-specific processes in individual tissues (**Figure 2**). Human-specific pathways in vascular tissue analysis include a host of immune related signals (leukocyte transendothelial migration, viral myocarditis, and TLR-9 cascade) as well as intricate signaling cascades including GPCR and PDGF signaling, and more general terms such as diabetes pathway and metabolism pathways. Among these, leukocyte transendothelial migration and diabetes pathways were shared between species in liver (**Figure 2, Suppl Table S3**). In liver, human-specific CAD pathways include immune system terms (interferon alpha/beta signaling, BCR signaling, and MHC class II antigen presentation), carbohydrate and BCAA metabolism, lysosome, neurotrophin signaling, and axon guidance pathways, among which BCAA and carbohydrate metabolism pathways were found to be shared between species in the vascular tissue-based analysis.

Mouse-specific atherosclerosis mechanisms identified in the aorta include signaling by insulin receptor, EGFR, ERBB2, NGF, and TGF-beta signaling, axon guidance, VEGF and VEGFR pathways, and Tap63 and DeltaNp63 pathways (**Suppl Table S2**). Some of the mouse-specific atherosclerosis pathways found in the aorta were identified as common to both species in liver tissue such as fatty acid synthesis, Jak-STAT and Wnt signaling. In liver tissue, mouse-specific pathways include toll-like receptor signaling, amino acid metabolism (arginine, proline, glycine, serine, and threonine), phospholipid metabolism, metabolism of non-coding RNA, binding and uptake of ligands by scavenger receptors, and mitochondrial transcription pathways (**Suppl Table S2**). TLR signaling pathway was found to be mouse-specific in liver, whereas it was human-specific in vascular tissues. Similarly, pathways such as axon guidance and developmental biology were mouse-specific in aorta, but human-specific in liver. Hence, some of the atherosclerosis pathways can be shared between species in a manner that is not matched by tissue-type.

### Identifying key driver (KD) genes in CAD-associated supersets shared between mouse and human

We identified KDs, which are potential key regulatory genes, within the CAD-associated gene sets using the Key Driver Analysis (KDA) in the Mergeomics pipeline (Ding et al., 2021; Shu et al., 2016). The KDA procedure maps the tissue-specific CAD-associated gene sets onto a tissue-matched gene regulatory network to predict KDs (see Methods). Our analysis utilized Bayesian Networks (BNs), which incorporate gene expression patterns with genetic information and causal inference. Hence, BNs can reveal causal regulatory relationships between genes and enable the identification of potential regulators within the CAD-associated genes, canonical pathways or annotated co-expression modules.



**Figure 2**

Shared and species-specific biological pathways.

In vascular tissues, one of the top KDs for the shared CAD/atherosclerosis pathways between species is *ZHX2*, whose subnetwork neighbors are highly enriched for genes in a co-expression module annotated with RXR/VDR pathway, post translational protein modification, and endocytosis terms (**Figure 3A** [↗](#)). Other top ranked KDs include *MYLK*, *FLNA*, *ACTA2*, *NCAM1*, and *FOXC1*, which are associated with core matrisome, focal adhesion, and vascular smooth muscle contraction processes modules; *CEP350*, which is associated with a cell cycle, DNA replication, and B cell receptor activation module; *ASB5*, *MYF6*, *CACNA1S*, and *AMPD1* for a cardiac muscle contraction-associated module; *AGPAT1*, which is associated with a module annotated with metabolism of nucleotides and aminoacyl tRNA biosynthesis; *FLNA*, *CNN3*, and *MYL9*, which are associated with an ECM related module; and lastly *MTA2*, which is associated with metabolism of carbohydrates, glycosaminoglycan degradation, and lysosome terms.

For liver tissue, the predicted KDs for the shared causal atherosclerosis/CAD pathways between mouse and human (**Figure 3B** [↗](#)) include: *NCKAP1L* and *INPP5D* for a Rho GTPase signaling module; *ARNTL* and *TEF* for circadian rhythm-related terms and pyrimidine metabolism modules; *COL1A1* and *COL6A3* for an ECM organization module; *RAC2* and *APBB1IP* for a platelet activation signaling and aggregation module; and lastly *SQLE* and *ACSS2* for a metabolism of lipids and lipoproteins module, which can be considered as a positive control pathway due to the critical role of circulating apoB lipoproteins in atherosclerosis and the central role of the liver in regulating their levels in both mice and humans.

Because KDA cannot predict directionality of the effects of KDs on CAD risk, we examined the correlation between KDs and atherosclerosis-relevant traits in the atherosclerosis HMDP as a means to suggest directionality. We found numerous significant positive or negative correlations for the vascular tissue (**Suppl Table S4**). For example, KDs *Agpat1* and *Zhx2* correlated positively with aortic lesion area, whereas *Cnn3* correlated negatively with aortic lesion area. Similarly, when querying the liver KDs in the atherosclerosis HMDP liver tissue, we found *Cidec* is negatively correlated with aortic lesion area as well as numerous KDs including *Inpp5d* and *Nckap1l* positively correlated with aortic lesion area (**Suppl Table S5**).


## KDs for species-specific CAD supersets

For human-specific vascular pathways, we identified *FNBP4*, *MYSM1*, *GC*, and *HPX* as the top KDs for a fibrin clot clotting cascade and chylomicron mediated lipid transport pathways module; *PLCB2* and *SYK* for a leukocyte transendothelial migration module; and *LCK* and *CCL5* for a cell adhesion module (**Figure 4A** [↗](#)). For human-specific liver pathways, we identified *MCM5* and *MCM6* as KDs for a cell cycle module; *MX1*, *ISG15*, and *IRF7* for an interferon alpha/beta signaling module; *ACADM* for a module annotated with BCAA degradation; and lastly, *NNMT* for an IL6/7 signaling module (**Figure 4B** [↗](#)).

For mouse-specific vascular pathways, numerous KDs were identified: *CLEC1A*, *DLL4*, *MYCT1*, *FLT1*, and *MYO5C* for a VEGF/VEGFR pathway and axon guidance module; *CEP350*, *MALAT1*, and *UTRN* for a fatty acid synthesis and ERBB2 signaling pathway module; *C2orf54*, *EHF*, *CRABP2*, *SLC46A2*, and *SOX2* for a Tap63 and DeltaNp63 pathways module (**Figure 4C** [↗](#)). For the mouse-specific liver atherosclerosis pathways, *PTPRB*, *KDR*, *OIT3*, and *CYP4B1* were found to be the top KDs for a VEGF/VEGFR module; *TMEM43*, *MTMR11*, *PLEKHA1*, and *SCNN1A* were the top KDs of amino acid metabolism pathways (arginine and proline metabolism, glycine, serine, threonine metabolism) and cardiac EGF pathway modules (**Figure 4D** [↗](#)).

Examining the KD-trait correlations in HMDP showed many of these KDs are positively correlated (e.g., *Dock2*, *Irf8*, and *Zap70*) or negatively correlated (e.g., *Utrn*) with aortic lesion area in the atherosclerosis HMDP aorta tissue, or positively (e.g., *Ifi44*, *Irf7*, *Mx1*, *Nnmt*, and *Rtp4*) or negatively (e.g., *Acadm* and *Ets2*) correlated with aortic lesion area in the atherosclerosis HMDP liver (**Suppl Table S4;S5**).





**Figure 3**

**Shared Networks between mice and humans.**

(A) Vascular (B) Non-vascular. Red border diamonds represent recent CAD GWAS hits and pink border diamonds represent GWAS hits pre-CARDIOGRAM+C4D GWAS hits.





Figure 3 (continued)



**Figure 4**

**Species Specific Networks.**

(A) Human Vascular (B) Human Non-vascular (C) Mouse Vascular (D) Mouse Non-vascular. Red border diamonds represent recent CAD GWAS hits and pink border diamonds represent GWAS hits pre-CARDIOGRAM+C4D GWAS hits.

## Comparison of KDs and pathways with known CAD/Atherosclerosis genes and processes in shared networks

Our analysis highlights a number of previously known CAD/atherosclerosis associated genes as KDs and commonly associated biological processes with CAD/atherosclerosis to be shared between species but also uncovers those less known or frequently associated to play a role in CAD development. For example, within vascular tissues (**Figure 3A** [↗](#)), we find a number of genes such as *NCAM1*, *MYLK*, and *ACTA2*, all of which have previously shown to have a link with CAD but with limited validation ([Erbilgin et al., 2018](#) [↗](#); [Ghosh et al., 2015](#) [↗](#); [Wang et al., 2007](#) [↗](#); [Yuan, 2015](#) [↗](#)). Within the shared CAD/atherosclerosis liver network between species (**Figure 3B** [↗](#)), *APBB1IP*, *PTPRC*, *NCKAP1L* and *INPP5D* were captured as potential novel KDs which again have not been strongly investigated, validated or implicated in CAD previously. However, the associated biological pathways of these key driver genes, including Rho GTPase signaling, hemostasis, and platelet activation and aggregation have all been repeatedly captured in CAD. Therefore, our analysis highlights novel regulators of these common CAD/atherosclerosis pathways.


## In silico validation of CAD-associated networks through the use of single cell transcriptome data

To validate the potential regulatory role of the KDs on their surrounding subnetwork genes, and to pinpoint the potential cell types that they may be contributing through, we utilized mouse single-cell RNA-sequencing data from the aorta ([Wirka et al., 2019](#) [↗](#)) and liver tissues ([Wang et al., 2021](#) [↗](#)).

To validate our vascular tissue CAD/atherosclerosis networks (KDs and their direct edge connections), we compared *ApoE*<sup>-/-</sup> mouse aorta single-cell gene expressions at baseline condition and after the 8-week high-fat diet (HFD) treatment. We found that the subnetworks driven by the KDs *ACTA2*, *FLNA*, *MYLK*, and *MYL9* exhibited significant changes in expression between diet conditions in smooth muscle cells (SMCs) (**Figure 5A-D** [↗](#)), thus highlighting the validity of the network structure for these subnetworks and potentially their contribution to CAD development via SMCs. This is further supported in the literature, as *ACTA2* mutations in SMCs have been linked to occlusive vascular disease via increased SMC proliferation ([Guo et al., 2009](#) [↗](#)). Our findings at the cellular level within SMCs suggest the neighboring subnetwork genes of *ACTA2* cooperate with this KD to contribute to atherogenesis and CAD progression. Also, in regard to the KD *FLNA*, interaction between G protein-coupled P2Y<sub>2</sub> nucleotide receptor (P2Y<sub>2</sub>R) and FLNa, an actin-binding protein encoded by *FLNA*, promotes SMC spreading, a hallmark characteristic in atherosclerosis development ([Yu et al., 2008](#) [↗](#)). Lastly, modification of MLCK, encoded by KD *MYLK* has been shown to disrupt the ability of aortic SMCs to generate force, leading to compromised contractile function ([Huang et al., 2018](#) [↗](#)), which may play an important role in CAD.

Due to the lack of single cell datasets for the liver for CAD studies, we utilized single cell data for a common comorbidity of CAD, non-alcoholic steatohepatitis (NASH), which is an advanced stage of non-alcoholic fatty liver disease involving liver inflammation and damage and linked to obesity, insulin resistance, and CAD. We found that the KD *OIT3* and its predicted surrounding network genes showed significant changes in expression between healthy and NASH states across multiple cell types such as hepatic stellate cells, hepatocytes, mononuclear phagocytes, and T cells (**Figure 5E-H** [↗](#)).

To ensure the observed gene expression changes in the KDs and their subnetwork genes validated above were not random in single cell data, we chose five random genes and their subnetwork genes as negative controls to test their expression changes between control and disease states. Indeed, these randomly selected genes did not show statistically significant changes.



**Figure 5**

**In silico validation of KDs and their subnetwork genes and associated cell type.**

(A-D) Aorta KDs and subnetwork genes. (E-H) Liver OIT3 and subnetwork genes. Five end genes are randomly selected genes.

\* indicate  $p < 0.05$

## In silico validation of CAD-associated KD networks through the use of the latest CAD GWAS

To test whether our CAD subnetworks predict new CAD GWAS loci, we overlaid hits from a more recent CAD GWAS (Tcheandjieu et al., 2022 [↗](#)), which was not used in our analysis, as well as hits from prior CAD GWAS ( $p < 5 \times 10^{-8}$ ) onto the shared CAD subnetworks between species. We found that KDs *FOXC1* in the shared vascular network and *ARNTL* in the shared liver CAD network were among GWAS hits. Additional GWAS hits in the shared cross-species CAD subnetworks were peripheral nodes (e.g. *CETP*, *PLCG2*, *BASP1*, *MSR1*, *ST5*, *ASAP2*) (Figure 3A;3B [↗](#)).

## Discussion

In order to understand the key similarities and differences between mouse and human in atherosclerosis/CAD-pathogenesis, we carried out a cross-species comparison of the genetically driven atherosclerosis/CAD mechanisms between mouse and human by integrating multiomics data. We observed a high ratio of overlap between species in genetically driven pathways (~74% in aorta and ~80% in liver), which include established CAD processes (e.g. metabolism of lipid, lipoproteins and fatty acids), as well as more novel processes (e.g. asparagine N-linked glycosylation). Given the high ratio overlap between species for genetic pathways, we can highlight the importance of the *in vivo* mouse model for understanding human CAD. More importantly, our results shed light on when to utilize mouse models for translational benefit to humans by focusing on the shared pathways and networks, and when we should look to alternative animal models for processes which are not shared between mouse and human (Gistera et al., 2022 [↗](#)).

Our data-driven multiomics analysis confirmed a number of causal pathways that were previously reported to be shared between species in a previous study based on literature review: platelet activation and signaling, metabolism of lipid and lipoproteins, cholesterol biosynthesis, cell cycle pathways, focal adhesion, and Jak-STAT signaling (Von Scheidt et al., 2017 [↗](#)). The previous study focused on CAD genes curated from the literature without considering the tissue context; here, our data-driven approach uniquely indicates that these shared pathways are involved in both vascular and non-vascular tissues in both species. Additionally, unlike the earlier studies, we incorporated CAD GWAS, thereby providing genetic evidence on how these pathways relating to plaque initiation, buildup, and thrombosis genetically drive CAD/atherosclerosis in both species. In addition to the replicated pathways, our data-driven approach also uniquely uncovered ECM, mitochondria function (oxidative phosphorylation, TCA cycle, respiratory electron transport), MAPK signaling, membrane trafficking, and notch signaling pathways to be shared across tissues between species. Since these are shared between species, targeting them in mice may lead to similar results when studying cardiovascular diseases in humans.

Our tissue-specific network analysis also revealed interesting tissue-specificity in the shared cross-species pathways. For instance, unique vascular tissue pathways include apoptosis, vascular smooth muscle contractions, and RXR/VDR pathways, all of which have been previously linked to CAD. We observed that some of the causal CAD pathways shared between species in a single tissue were identified as species-specific in the other tissue. For instance, BCAA catabolism pathway was found to be shared between mouse and human in vascular tissue, whereas it was also identified as human-specific in liver. Similarly, the leukocyte transendothelial migration pathway was shared between species in liver, whereas it was human-specific in vascular tissues. We also identified species-specific pathways in each tissue individually. For instance, signaling by insulin receptor was found to be mouse-specific in aorta, but the diabetes pathway was impaired in both mouse and human liver. These results point to the importance of taking the tissue context into consideration when translating genes and pathways between mouse and human.

After identifying potential causal atherosclerosis/CAD pathways, we identified the top KD genes of the shared and species-specific pathways in each tissue. *ZHX2* was found to be one of the top KDs in an aorta coexpression module shared between mouse and human (**Figure 4A**). *ZHX2* was previously identified as a candidate gene for CAD, and its proposed mechanism was through modulating macrophage apoptosis (Sen et al., 2014).

Since it was also shown to be a regulator of major genes behind lipoprotein metabolism (Gargalovic et al., 2010), it may also contribute to the development of atherosclerosis via lipid modulation. However, our network modeling indicates *ZHX2* has additional functions related to RXR/VDR, protein modification, and endocytosis in vascular tissue. Thus, future experimental testing is warranted to further explore the diverse mechanisms through which *ZHX2* modulates atherogenesis. In liver tissue, a notable KD for a cross-species module involved in immune response and platelet function includes *RAC2* (**Figure 3B**). Previously, *RAC2* was shown to prevent progressive calcification in experimental atherogenesis through the suppression of Rac1-dependent IL-1 $\beta$ , and in CAD patients it has been found that *RAC2* expression was decreased while IL-1 $\beta$  expression is increased (Ceneri et al., 2017).

Through our *in silico* single cell analyses in mouse aorta and liver, we also highlight various other KDs to be taken into further consideration. In the mouse aorta, changes in expression levels of genes within subnetworks of KDs *ACTA2*, *FLNA*, *MYL9*, and *MYLK* proved significantly robust in SMCs between control and a pro-atherogenic condition (**Figure 5**). In the liver, the KD *OIT3* and its subnetwork genes showed robust changes in multiple cell types between NASH and control conditions. Previously, *OIT3* has been suggested to contribute to hepatic triglyceride homeostasis and very-low-density lipoprotein secretion, and hepatic *OIT3* levels have been shown to be elevated in mice fed with HFD (Wu et al., 2021). Targeting *OIT3* may help treat both NASH and CAD. Importantly, the representation of our bulk aorta and liver tissue CAD networks within specific cell types helps provide support for the predicted gene networks interactions and warrants future *in vivo* cell-type specific validation studies. In addition, through overlaying the latest human CAD GWAS hits onto our networks, we were able to highlight that our networks captured new GWAS hits such as KD *ARNTL* and peripheral network genes (e.g. *ASAP2*, *ST5*, *MCF2L*, *CLDN5*, *TNS1*, and *C5*) (**Figure 2,3,4**). Finding more GWAS hits to be peripheral nodes in the networks supports the notion that important regulators may not always harbor common variations due to evolutionary constraints. GWAS hits being found as peripheral hits is consistent with numerous prior studies (Blencowe et al., 2021; Goh et al., 2007; Krishnan et al., 2018; Zhao et al., 2019a).

We acknowledge the following limitations of this study. First, we did not use the most recent and largest GWAS dataset as our initial input for our analysis. This potentially puts us at risk of not capturing the full array of biology. However, despite our input GWAS dataset not being the most recent, as mentioned above, we were able to capture *ARNTL* as a key driver gene connected to two more recent CAD GWAS hits *ASAP2* and *ST5* (Aragam et al., 2022; Koyama et al., 2020) and numerous other GWAS hits as network neighbors. Particularly, the identification of such genes acts as a form of validation of our network predictions and their importance in CAD pathogenesis. We also acknowledge that there are multiple approaches that can be used to map SNPs to genes beyond eQTLs such as splicing, protein, and epigenome QTLs (sQTLs, pQTLs, epiQTLs). Utilizing additional mapping methods as well integrating other omics layers such as metabolomics and plasma proteomics in the future will potentially highlight additional findings, which can complement our current tissue specific gene network/pathway results and possibly capture cross-tissue interactions mediated by secreted proteins and metabolites. In addition, it is important to note in this study that we did not regress out sex effects and we only examined HMDP as the mouse model of atherosclerosis. Therefore, there may be other pathways and genes that have been identified to be human specific in this study because they are missed in HMDP but can be captured in other mouse models, such as PDGF signaling found in the ApoE<sup>-/-</sup> model (Kim et al., 2023). Along, with some pathways not being captured, we also highlight some interesting

pathways being uncovered in vascular tissue, which have had little literature to support their role in atherosclerosis including gluconeogenesis and BCAA catabolism (Zhenyukh et al., 2018 [↗](#)), we acknowledge that future studies will need to further investigate such pathway predictions but also note that these pathway terms have many shared genes with more commonly known processes such as the TCA cycle, which may be indicative of energy metabolism in the vasculature in CAD development. Lastly, we could not identify single cell datasets that matched the conditions of the human and mouse GWAS datasets used in our data driven approach. Nevertheless, the network structures of the CAD KD genes appeared to be robust in conditions relevant to CAD, such as high fat diet feeding in ApoE<sup>-/-</sup> and NASH mice.

In summary, our comprehensive, data-driven, and integrative genomics study, highlights the similarities and differences in the molecular processes and key regulator genes involved in atherosclerosis and CAD between species. The incorporation of genetic information provides the potential causal nature of the pathways and regulators in CAD development. The novel insights highlighted here can enable the development of more effective therapies targeting the shared key regulator genes and pathways in light of their translatability from mouse to humans. More importantly, we are also made aware of the CAD human biology not captured in our mouse model, where other animal models should be considered. Both the shared processes between mouse and human and the human-specific processes warrant further investigation, and identifying non-mouse or additional mouse models that recapitulate the human-specific pathways is necessary for mechanistic and clinical translation.

## Methods

### Atherosclerosis study of Hybrid Mouse Diversity Panel

The Hybrid Mouse Diversity Panel (HMDP) study design for atherosclerosis was previously described (Bennett et al., 2015 [↗](#)). Aortic lesion area phenotype was used as the hallmark of atherosclerosis. C57BL/6 mice carrying the human transgene for cholesteryl ester transfer protein were purchased from the Jackson Laboratory, and mice with the human apolipoprotein E-Leiden variant were obtained from Dr. Havekes (Van den Maagdenberg et al., 1993 [↗](#)). These strains were interbred to generate double transgenic mice, which were then bred to female mice from ~100 inbred or recombinant inbred strains obtained from the Jackson Laboratory. Female mice from the 100 strains were first fed with a chow diet for 8 weeks, and then placed on a high fat high cholesterol diet (33% kcal fat, 1% kcal cholesterol) until 24 weeks of age (Research Diets D10042101). Mice were then sacrificed for tissue collection. All experimental procedures were approved by the UCLA animal research committee.

### Atherosclerotic lesions in HMDP mice

Proximal aortic lesion area had been carried out as previously described (Bennett et al., 2015 [↗](#); Mehrabian et al., 1993 [↗](#); Shih et al., 2000 [↗](#)). The aorta was cleaned with phosphate buffered solution and embedded in the optimal critical temperature compound. Oil Red O was used to stain frozen sections of 10  $\mu$ m. Lesion area was quantified in each third section across the proximal aorta. The aortic lesion size was normalized using the Yeo-Johnson approach (Yeo and Johnson, 2000 [↗](#)).

### Gene expression analyses of aorta and liver tissues in HMDP

Tissue collection process for the expression data from aorta and liver tissues that were used in our analysis was previously described (Bennett et al., 2015 [↗](#)). Whole aorta was cleaned of peri-adventitial adipose and immediately frozen at the time of euthanasia. The liver tissues were precisely dissected, and a 50- $\mu$ g section from the left lobe was snap-frozen. Qiagen RNeasy kit was used to isolate total RNA for each tissue. Affymetrix HT-MG\_430 PM microarrays were used to



determine the genome-wide expression profiles for each tissue of female mice from 101 strains for aorta (1 to 10 aorta samples per strain, 366 samples in total) and 96 strains for liver (1 to 4 samples per strain, 220 samples in total) from the HMDP mice (Bennett et al., 2015 [↗](#)). Additionally, we used gene expression data from an earlier HMDP study, which includes control mouse samples (Bennett et al., 2010 [↗](#)). From these control mice, 188 aorta and 288 liver samples were collected (Bennett et al., 2010 [↗](#)).

## Genome-wide association analysis of aortic lesion area and tissue-specific eQTLs in mice

Genotypes for 625 mice from 95 inbred and recombinant inbred mouse strains were obtained from Jackson Laboratories using the Mouse Diversity Array (Yang et al., 2009 [↗](#)). SNPs with poor quality were removed (Bennett et al., 2015 [↗](#)). Then, the SNPs with a minor allele frequency (MAF) of <10% and a missing genotype frequency of >10% were removed, resulting in 212,765 SNPs for the downstream analysis. Genome-wide association mapping of the aortic lesion size was performed using factored spectrally transformed linear mixed models (FaST-LMM) based on a linear mixed model to correct for population structure (Bennett et al., 2015 [↗](#)). Tissue-specific eQTLs were also calculated using FaST-LMM and the false discovery rate (FDR) was estimated by the *q* value approach (Storey and Tibshirani, 2003 [↗](#)) to adjust for multiple testing. In our analysis, we incorporated aorta tissue eQTLs from the atherosclerosis study for HMDP (Ath-HMDP) with aortic tissue eQTLs of another HMDP study, which included chow diet fed (control) HMDP mice that do not have atherosclerosis (Bennett et al., 2010 [↗](#)). Similarly, we incorporated liver tissue eQTLs from multiple HMDP studies, including Ath-HMDP, control HMDP mice (Bennett et al., 2010 [↗](#)), and high fat/high sucrose-fed HMDP mice with non-alcoholic fatty liver disease (NAFLD) (Parks et al., 2013 [↗](#); Parks et al., 2015 [↗](#)). In our study, cis-eQTLs, which are located within  $\pm 1$ Mb of the genes' transcription start and end sites, and trans-eQTLs, which are identified as all other eQTL associations, were used with an FDR<5% cutoff for both. For each HMDP study, FDR scores of the cis- and trans-eQTLs were calculated independently (for the FDR<5%, e.g.  $P < 6.4 \times 10^{-3}$  for Ath-HMDP aorta cis-eQTLs,  $6.7 \times 10^{-3}$  for Ath-HMDP liver cis-eQTLs,  $P < 1.3 \times 10^{-5}$  for Ath-HMDP trans-eQTLs for both aorta and liver (Bennett et al., 2015 [↗](#));  $P < 1.4 \times 10^{-3}$  and  $P < 6.1 \times 10^{-6}$  for NAFLD-HMDP study cis-eQTLs and trans-eQTLs, respectively). Hence, we used a single, but stringent FDR<5% cutoff for all eQTL resources from multiple HMDP studies to provide consistent accuracy. In total, we used ~1.5million eQTL associations in aorta tissue and ~3million eQTL associations in liver.

## Human GWAS for coronary artery disease from the CARDIoGRAMplusC4D consortium

The coronary artery disease genome-wide replication and meta-analysis (CARDIoGRAM) and the coronary artery disease genetics (C4D) consortium (CARDIoGRAMplusC4D) collaborated and combined genetic data from diverse large-scale studies to determine risk loci for CAD and myocardial infarction (MI) in the human genome. In our analysis, we used the 1000 genomes-based GWAS from the CARDIoGRAMplusC4D, which is a meta-analysis of GWASs mainly based on European, South Asian, and East Asian descent, and imputed them through the 1000 Genomes phase 1 v3 training set with 38 million variants (Nikpay et al., 2015 [↗](#)). In total, the GWAS includes 60,801 CAD cases, 123,504 control samples, and 9.4 million variants.

## Expression QTL data sets from the STARNET and GTEx

We used two different gene expression data resources: one from Stockholm-Tartu Atherosclerosis Reverse Network Engineering Task (STARNET) (Franzén et al., 2016 [↗](#)), and the other from the Genotype-Tissue Expression (GTEx) project (Lonsdale et al., 2013 [↗](#)). We leveraged tissue-specific eQTLs from atherosclerotic aortic root (AOR), atherosclerotic-lesion-free internal mammary artery (MAM), and liver tissues from the STARNET cohort, which consists of ~600 CAD patients of Caucasian descent. Data collection and processing for STARNET were previously described

(Franzén et al., 2016 [↗](#)). AOR, MAM, and liver tissue samples were collected from 539, 552 and 576 individuals in total, respectively (Franzén et al., 2016 [↗](#)). Written informed consent was obtained from all patients. OmniExpress Exome array was used to genotype the DNA and >14 million variant calls were identified (6,245,505 variants with a MAF>5%). HiSeq 2000 platform was used to perform RNA-sequencing, Matrix eQTL R-package (Shabalin, 2012 [↗](#)) was used to identify the tissue-specific eQTLs, cis-eQTLs were defined within a  $\pm 1$ Mb window from the center of the gene, trans-eQTLs were identified as all other eQTL associations, cis-eQTL P-values were identified through a permutation test (for FDR<5%,  $P=0.006$  for AOR,  $P=0.004$  for MAM,  $P=0.001$  for liver), and trans-eQTL P-values were corrected for multiple testing through the Bonferroni correction in (Franzén et al., 2016 [↗](#)). We used eQTL cutoff threshold FDR<5%.

GTEx consortium provides a publicly available human tissue bank with an enormous amount of data encompassing the associations between genotype and tissue-specific gene expression patterns in 54 tissues (Lonsdale et al., 2013 [↗](#)). In our analysis, we used tissue-specific transcriptome and eQTL data from coronary artery, aortic artery, and liver tissues from the GTEx biobank as these were the most relevant tissues in CAD. Transcriptome data was used to construct tissue-specific coexpression networks, and eQTLs were used in our integrative framework, Mergeomics (Shu et al., 2016 [↗](#)), to map gene sets to the CAD-GWAS SNPs (see MSEA in Methods). HiSeq X, HiSeq 2000, Illumina OMNI 5M and 2.5M arrays were used for genome sequencing. SNPs with a MAF  $\geq 1\%$  were kept for downstream analysis. Illumina TrueSeq RNA sequencing and Affymetrix Human Gene 1.1 ST Expression Array (v3) were used for gene expression data. As detailed in Lonsdale et al 2013 [↗](#) (Lonsdale et al., 2013 [↗](#)), RNA-sequencing data was aligned to the hg19/GRCh37 human reference genome using STAR v2.4.2a, based on the GENCODE-v19 annotation, and the GTEx pipeline was detailed in [47]. In the GTEx database, cis-eQTLs were identified within  $\pm 1$ Mb of the genes' transcription start sites using the FastQTL tool (Ongen et al., 2016 [↗](#)), which utilizes a linear regression model-based hypothesis testing. P-values were adjusted using the q-value method (Storey and Tibshirani, 2003 [↗](#)) and significant eQTL associations with an FDR<5% threshold were used for each tissue. AOR and MAM tissue eQTLs from STARNET were combined with the vascular tissue (i.e. coronary and aortic arteries) eQTLs from GTEx. Similarly, liver tissue eQTLs from STARNET and GTEx were combined to use in our liver-specific analysis.

## Reconstruction of tissue-specific co-expression networks from liver and vascular tissue transcriptome data

Tissue-specific coexpression networks were constructed from aorta and liver gene expression data of the HMDP mice (Bennett et al., 2015 [↗](#); Bennett et al., 2010 [↗](#)) and from aortic arteries, coronary arteries, and liver gene expression data from the GTEx biobank (Lonsdale et al., 2013 [↗](#)), using two network approaches: Weighted Gene Co-expression Network Analysis (WGCNA) (Langfelder and Horvath, 2008 [↗](#)) and Multiscale Embedded Gene Co-expression Network Analysis (MEGENA) (Song and Zhang, 2015 [↗](#)). The power of WGCNA for identifying biologically meaningful and relevant modules has been demonstrated in multiple studies. However, the resulting large-sized modules which can include thousands of genes, may include noise and distract our focus in downstream analysis. However, the other network method, MEGENA can define smaller and more coherent modules that are also biologically relevant, which overcomes the limitations of WGCNA. Additionally, each gene can be assigned into multiple modules by MEGENA, which overcomes another limitation of WGCNA and fits better with the known biology. In our study focusing on fatty liver disease, we showed these two methods complement each other while uncovering hidden parts of the biology that were missed by each method individually (Krishnan et al., 2018 [↗](#)). Both network methods are based on hierarchical clustering to assign co-regulated genes into the same coexpression module. Agglomerative hierarchical clustering is used in WGCNA, whereas divisive clustering is used in MEGENA. Gene-clusters are identified by merging (in agglomerative) or splitting (in divisive) based on a distance measure (e.g.  $1 - |\text{correlation}|$ ). In WGCNA, 1 minus topological overlap matrix (TOM), hence  $\text{dissTOM} = 1 - \text{TOM}$ , was used as the distance measure. TOM is based on the correlation score (edge weight) between two

genes (nodes) but also considers the edge weights of common neighbors of these two nodes in the network. To calculate the distance between two clusters, average disSTOM score of all gene pairs (each pair includes one gene from each cluster, while comparing 2 clusters) is used. In MEGENA, a shortest path distance (SPD) based distance measure is used. To create compact modules, a nested k-medoids clustering, which defines k-best clusters at each step that minimizes the SPD within each cluster, is used. Nested k-medoids clustering is ran until no more compact child cluster can be defined. Unlike WGCNA, MEGENA performs clustering in a multi-scale manner, which provides us an alternative set of modules at each scale despite using the same gene expression input. Multi-scale clustering assigns a gene into multiple modules from different scales.

After identifying the WGCNA and MEGENA modules, we annotated each module with its functions by using the previously curated biological pathways taken from MSigDB database (Subramanian et al., 2005) that incorporates pathways from Biocarta, KEGG, and Reactome databases based on a hypergeometric test (one-tailed Fisher Exact test). Bonferroni correction was used to correct for multiple testing. Pathways with a corrected  $P < 5\%$  and sharing  $\geq 5$  genes with a given module were considered significant. The top 5 significant pathways were used to annotate each module. For modules that did not have any significant annotation terms, a less stringent cutoff of raw  $P < 5E-3$  and  $\geq 5$  shared genes were used. These modules are differentiated with an asterisk (\*) in Figures and Tables.

## Tissue-specific Bayesian network construction with RIMBANet

Bayesian networks (BNs) represent a class of gene regulatory networks, which can demonstrate the directed causal relationships between genes by using genetic and gene expression information, as well as previously known regulatory relationships between genes. In the BNs, each edge is directed to a child node from a parent node, where the BN represents a multivariate probability distribution, and the state of each node is estimated by the states of its parent nodes. We leveraged the Reconstructing Integrative Molecular Bayesian Networks (RIMBANet) tool (Zhu et al., 2012; Zhu et al., 2007; Zhu et al., 2008) to construct tissue-specific BNs using aorta and liver gene expression data from the HMDP study, focusing on atherosclerosis, which involved 366 aorta samples from 101 mouse strains and 220 liver samples from 96 strains (Bennett et al., 2015) as well as human GTEx aorta, coronary artery and liver gene expression data. Since the computational cost and computing time of RIMBANet are both high, we selected the top 5000 variable genes in the expression data to construct our networks. On average, it took ~2 weeks to construct a BN with 5000 genes. The expression values of each gene across all samples were discretized into 3 clusters as lowly, mildly, and highly-expressed using k-means clustering (Alpaydin, 2010). The state transitions of each node were formulated with Markov chain based on the discretized gene expression data. RIMBANet aims to find a network, which can explain the observed (gene expression) data in the best way and aims to maximize a joint probability function on the network nodes given the data. Given the expression data  $D$ , the joint probability of a network model  $M$ , i.e.  $P(M|D)$ , can be predicted as a function of the prior probability of model  $M$  without any observations, i.e.  $P(M)$ , and the likelihood of observing data  $D$  given the model  $M$ , i.e.  $P(D|M)$ . Thereby,  $P(M|D) \approx P(M) \times P(D|M)$ . RIMBANet is based on Markov chain and because of the Markov equivalence concept, many of the edge directions in the network can be changed without affecting how well the model  $M$  fits the data  $D$ . There can be a large number of network models, which can explain the same observed data  $D$  equally well. Hence, it is necessary to narrow down the search-space while searching for the best-fitting network model. Using prior information based on the genetic data, eQTLs, tissue-specific transcription factor and target gene pairs can ensure narrowing the search space (e.g. a cis-acting gene is more likely to be a parent node of trans-acting genes coinciding on the same eSNP). Since it is not possible to calculate the joint probabilities of all possible network models given the expression data  $D$ , RIMBANet employs a down-sampling method, namely Monte Carlo Markov Chain (MCMC) simulation, identifies a certain number (1000) of plausible networks, and calculates the joint probabilities of these networks. Then, these 1000 sampled networks are combined to obtain a consensus network, e.g. if an edge from node-A to node-B exists in at least 30% of the 1000 networks, this edge is kept in the

ultimate consensus network. BNs are directed acyclic graphs (DAG) by nature; thereby, the consensus network should also be a DAG, which is ensured by removing the weakest edges in a cycle that impairs the DAG nature of the network.

## Mergeomics Pipeline for multi-omic integration

Genetic (atherosclerosis GWAS in mouse, CAD-GWAS in human) and functional genomics data (eQTLs, coexpression modules) were integrated using our Mergeomics pipeline (Arneson et al., 2016 [DOI](#); Shu et al., 2016 [DOI](#)). Canonical pathways and coexpression networks that are genetically associated with atherosclerosis-GWAS (in mouse) or CAD-GWAS (in human) were identified in a species- and tissue-specific manner by using the Marker Set Enrichment Analysis (MSEA) procedure in Mergeomics. MSEA is used to map genes from each pathway (from Biocarta, KEGG, Reactome) or coexpression module (from MEGENA or WGCNA) to an eSNP set via eQTLs of the corresponding tissue of the corresponding species. As mentioned earlier, we used significant eQTL associations (FDR<5%) from each tissue and species, and trimmed eSNPs within the same linkage disequilibrium (LD) block, by keeping only one eSNP for each LD block for each species individually. LD block data was obtained using the PLINK2 tool (Chang et al., 2015 [DOI](#)) for both HMDP mice and 1000Genome phase 1-based GWAS that was used in humans. The eSNP sets that were mapped from each pathway or module (i.e. gene set) through LD-pruned eQTLs, were annotated with the *P*-values of corresponding SNPs from the disease-GWAS of corresponding species. Then, we used a modified chi-square statistic for the enrichment assessment, which is summarized across a range of quantile-based cutoffs for the GWAS, instead of depending on a single GWAS *P*-value cutoff. This test analyzes the significance of enrichment for stronger disease-GWAS *P*-values, by comparing the GWAS *P*-values of a given eSNP set against the eSNP sets that were mapped from randomly generated gene sets. Our MSEA approach is based on a set of quantile-based cutoffs and is not based on a single GWAS *P*-value cutoff; hence it avoids artefacts while producing more stable enrichment scores. The definition of the modified chi-square statistics used in the MSEA is:  $\chi = \sum_{i=1}^n \frac{O_i - E_i}{\sqrt{E_i + \kappa}}$ , where *O* and *E* are the numbers of the observed and estimated positive findings, respectively (i.e. findings above the *i*-th quantile point); *n* is the number of quantile points (10 points were identified ranging from the top 50% to top 99.9% signals based on the GWAS *P*-value rankings), and  $\kappa = 1$  is a stability parameter diminishing the artefacts for small eSNP sets with low expected counts. For the MSEA procedure, an FDR<5% cutoff was used, which is estimated by the Benjamini-Hochberg method (Benjamini and Hochberg, 1995 [DOI](#)) to identify significantly enriched gene sets for the disease-GWASs.

After identifying the significant disease-associated gene sets (pathways or modules) at FDR<5%, to reduce the redundancy in our findings, we merged the overlapping gene sets into non-overlapping supersets if they significantly shared their member genes, which is defined by a gene-overlapping ratio of >33% and Bonferroni corrected one-tailed Fisher's exact test (FET) *P*<5%. In some cases, a coexpression module and a canonical pathway, or two different coexpression modules, which were annotated with the same biological term, were not merged since they did not significantly share their member genes; hence we kept them as independent gene sets though they were annotated with similar or the same terms.

The second step of the Mergeomics pipeline, Weighted Key Driver Analysis (wKDA), was used to predict key regulator, or key driver (KD), genes within the CAD-associated supersets. The wKDA maps the member genes in each superset onto a tissue-specific gene regulatory network, which is a Bayesian network (BN) in our study. wKDA has been demonstrated to predict biologically meaningful KDs in our previous studies (Krishnan et al., 2018 [DOI](#); Mäkinen et al., 2014 [DOI](#); Zhao et al., 2016 [DOI](#)). In the current study, we first constructed aorta and liver tissue BNs, which include the causal and directed relationships between genes, using an established method RIMBANet (Zhu et al., 2012 [DOI](#); Zhu et al., 2007 [DOI](#); Zhu et al., 2008 [DOI](#)); then we mapped the CAD-associated supersets onto these BNs in a tissue-specific manner using wKDA to identify the KDs of each superset. wKDA uses a modified chi-square statistic, as defined for the MSEA, to assess the enrichment of member

genes of a given superset within the candidate KD's neighborhood in the BN, compared to that of a random gene chosen from the same BN. Similar to MSEA, the Benjamini-Hochberg method was used to correct *P*-values for the multiple hypothesis testing, and candidate genes with an FDR<5% were predicted as KDs of the genetic CAD supersets. KDs of each shared and species-specific CAD supersets were ranked based on their FDR scores and the top KDs were identified. Then, subnetworks of the top KDs were extracted in each tissue BN by collecting network-neighbors of the top KDs as illustrated in **Figures 4** and **5**. We overlaid CAD GWAS hits into our subnetwork visualization where red border diamonds represent post 2017 CAD GWAS hits and pink border diamonds represent GWAS hits pre-CARDIOGRAM+C4D GWAS hits (pre 2017). Lastly, we queried the atherosclerosis HMDP aorta and liver tissues for significant (*p*-value<0.05) gene-clinical trait correlations for shared, human-specific, and mouse-specific KDs.

## Comparing the genetic CAD pathways and modules between mouse and human

After identifying the putatively causal and genetic atherosclerosis and CAD-associated biological mechanisms using the MSEA, we compared our findings from mouse and human in a tissue-specific manner. To identify shared gene sets between species, we matched pathways and coexpression modules by name and annotation terms, as well as applying an overlap analysis to identify the common mechanisms. We calculated 2-sided (mutual) overlapping ratios between the CAD-associated mechanisms identified for mouse and human using the Jaccard index,

$$JI = \frac{|A \cap B|}{|A \cup B|} = \frac{n}{|A| + |B| - n},$$

where *n* is the number of shared genes between supersets A and B, and

|A| is the number of genes in set A. We also calculated 1-sided overlapping ratios as either  $n/|A|$  or  $n/|B|$  to identify gene sets that are potentially a subset of a larger set, and we assumed the subsets to be shared between species, whose member genes are already covered by both sides. Additionally, we applied a hypergeometric test (one-tailed FET) between the CAD-mechanisms identified for mouse and human. If a CAD superset from either mouse or human satisfied one of the following conditions when compared to a CAD superset identified for the other species, it was defined as a shared pathway:

1. A two-sided overlap that is > 50% and a hypergeometric test adjusted *P*<5% or
2. A one-sided overlap that is > 90% and a hypergeometric test adjusted *P*<5%.

Occasionally, multiple pathways in mouse were found to be a subset (1-sided overlap >90%) of a single pathway in human (or vice versa), or the 2-sided overlapping analysis identified a pathway in one species to be matched to multiple pathways in the other species. Hence, the number of common pathways differs in each of the species as shown in **Figure 2** and Suppl Table S3.

## In silico validation of network structure through use of single cell datasets

FASTQ files from each study (Wirka et al., 2019) for aorta, (Wang et al., 2021) for liver were aligned to the mouse or human reference genome using Cell Ranger Software from 10x Genomics. Each dataset was analyzed using the R package Seurat version 4.0.3. The datasets were filtered for cells expressing fewer than 200 genes or greater than 7500 genes to account for potential doublet events in which two separate cells are processed together. The number of genes, percentage of hemoglobin markers, and percentage of mitochondrial genes were observed to ensure quality control; cells containing >6% mitochondrial genes were considered of poor quality in liver and >15% for aorta and removed from the dataset. Gene expression values were normalized as feature counts for each cell were divided by the total counts for the cell and multiplied by a scale factor of 10,000; this value was then natural log transformed using log<sub>1p</sub>. Top genes differentially expressed in each cell type cluster were identified by FindAllMarkers in Seurat and subsequently

used for further analysis of the datasets. Principal component analysis was performed for dimensionality reduction, and Uniform Manifold Approximation and Projection (UMAP) was then used for two-dimensional visualization of the clusters. FASTQ files for aorta and for liver may be found in the Gene Expression Omnibus database respectively with the primary accession code GSE131780 and GSE166178.

## Acknowledgements

MB was supported by the AHA Predoctoral Fellowship (829009) and UCLA IBP Hyde Fellowship. ZK was supported by AHA Postdoctoral Fellowship (17POST33670739) and UCLA Iris Cantor, XY is supported by NIH R01 HL147883, DK117850, AJL is supported by NIH R01 DK117850. JB acknowledges support from the Swedish Research Council (2018-02529 and [2022-00734](#)), the Swedish Heart Lung Foundation (2017-0265 and 2020-0207), the Leducq Foundation AteroGen (22CVD04) and PlaQOmics (18CVD02) consortia; the National Institute of Health-National Heart Lung Blood Institute (NIH/NHLBI, R01HL164577; R01HL148167; R01HL148239, R01HL166428, and R01HL168174), American Heart Association Transformational Project Award 19TPA34910021, and from the CMD AMP fNIH program.

## Author contributions

Writing of the manuscript: MB, ZK, JC, ZS, RBC, XY. Study Design: MB, ZK, AJL, JB, XY. Data contribution: AJL, JB. Data analysis: MB, ZK, JC, CM, ZS, NJ, NH, RBC, CP, SK, OF. Editing of manuscript and approval: MB, ZK, JC, CM, ZS, NH, NJ, RBC, CP, SK, OF, SW, JB, AJL, XY.

## References

- Alpaydin E. (2010) **Introduction to machine learning, 2nd edn. adaptive computation and machine learning**
- Aragam K.G., Jiang T., Goel A., Kanoni S., Wolford B.N., Atri D.S., Weeks E.M., Wang M., Hindy G., Zhou W., et al. (2022) **Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants** *Nat Genet* **54**:1803–1815
- Arneson D., Bhattacharya A., Shu L., Mäkinen V.-P., Yang X (2016) **Mergeomics: a web server for identifying pathological pathways, networks, and key regulators via multidimensional data integration** *BMC genomics* **17**
- Benjamini Y., Hochberg Y (1995) **Controlling the false discovery rate: a practical and powerful approach to multiple testing** *Journal of the Royal statistical society: series B (Methodological)* **57**:289–300
- Bennett B.J., Davis R.C., Civelek M., Orozco L., Wu J., Qi H., Pan C., Packard R.R.S., Eskin E., Yan M (2015) **Genetic architecture of atherosclerosis in mice: a systems genetics analysis of common inbred strains** *PLoS genetics* **11**
- Bennett B.J., Farber C.R., Orozco L., Kang H.M., Ghazalpour A., Siemers N., Neubauer M., Neuhaus I., Yordanova R., Guan B (2010) **A high-resolution association mapping panel for the dissection of complex traits in mice** *Genome research* **20**:281–290
- Blencowe M., Ahn I.S., Saleem Z., Luk H., Cely I., Mäkinen V.P., Zhao Y., Yang X (2021) **Gene networks and pathways for plasma lipid traits via multitissue multiomics systems analysis** *J Lipid Res* **62**
- Boyle E.A., Li Y.I., Pritchard J.K (2017) **An expanded view of complex traits: from polygenic to omnigenic** *Cell* **169**:1177–1186
- Ceneri N., Zhao L., Young B.D., Healy A., Coskun S., Vasavada H., Yarovinsky T.O., Ike K., Pardi R., Qin L (2017) **Rac2 modulates atherosclerotic calcification by regulating macrophage interleukin-1 $\beta$  production** *Arteriosclerosis, thrombosis, and vascular biology* **37**:328–340
- Chang C.C., Chow C.C., Tellier L.C., Vattikuti S., Purcell S.M., Lee J.J (2015) **Second-generation PLINK: rising to the challenge of larger and richer datasets** *Gigascience* **4**
- Ding J., Blencowe M., Nghiem T., Ha S.M., Chen Y.W., Li G., Yang X (2021) **Mergeomics 2.0: a web server for multi-omics data integration to elucidate disease networks and predict therapeutics** *Nucleic Acids Res* **49**:W375–W387
- Erbilgin A., Seldin M.M., Wu X., Mehrabian M., Zhou Z., Qi H., Dabirian K.S., Sevag Packard R.R., Hsieh W., Bensinger S.J (2018) **Transcription factor Zfx2 deficiency reduces atherosclerosis and promotes macrophage apoptosis in mice** *Arteriosclerosis, thrombosis, and vascular biology* **38**:2016–2027

Franzén O., Ermel R., Cohain A., Akers N.K., Di Narzo A., Talukdar H.A., Foroughi-Asl H., Giambartolomei C., Fullard J.F., Sukhvasi K. (2016) **Cardiometabolic risk loci share downstream cis-and trans-gene regulation across tissues and diseases** *Science* **353**:827–830

Gargalovic P.S., Erbilgin A., Kohannim O., Pagnon J., Wang X., Castellani L., LeBoeuf R., Peterson M.L., Spear B.T., Lusis A.J. (2010) **Quantitative trait locus mapping and identification of Zhx2 as a novel regulator of plasma lipid metabolism** *Circulation: Cardiovascular Genetics* **3**:60–67

Ghosh S., Vivar J., Nelson C.P., Willenborg C., Segrè A.V., Mäkinen V.-P., Nikpay M., Erdmann J., Blankenberg S., O'Donnell C (2015) **Systems genetics analysis of genome-wide association study reveals novel associations between key biological processes and coronary artery disease** *Arteriosclerosis, thrombosis, and vascular biology* **35**:1712–1722

Gistera A., Ketelhuth D.F.J., Malin S.G., Hansson G.K (2022) **Animal Models of Atherosclerosis-Supportive Notes and Tricks of the Trade** *Circ Res* **130**:1869–1887

Goh K.-I., Cusick M.E., Valle D., Childs B., Vidal M., Barabási A.-L (2007) **The human disease network** *Proceedings of the National Academy of Sciences* **104**:8685–8690

Guo D.C., Papke C.L., Tran-Fadulu V., Regalado E.S., Avidan N., Johnson R.J., Kim D.H., Pannu H., Willing M.C., Sparks E., et al. (2009) **Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease** *Am J Hum Genet* **84**:617–627

Huang J., Gao N., Wang S., Milewicz D.M., Kamm K.E., Stull J.T (2018) **Genetic approaches to identify pathological limitations in aortic smooth muscle contraction** *PLoS One* **13**

Khera A.V., Emdin C.A., Drake I., Natarajan P., Bick A.G., Cook N.R., Chasman D.I., Baber U., Mehran R., Rader D.J (2016) **Genetic risk, adherence to a healthy lifestyle, and coronary disease** *New England Journal of Medicine* **375**:2349–2358

Kim H.J., Cheng P., Travisano S., Weldy C., Monteiro J.P., Kundu R., Nguyen T., Sharma D., Shi H., Lin Y., et al. (2023) **Molecular mechanisms of coronary artery disease risk at the PDGFD locus** *Nat Commun* **14**

Koyama S., Ito K., Terao C., Akiyama M., Horikoshi M., Momozawa Y., Matsunaga H., Ieki H., Ozaki K., Onouchi Y., et al. (2020) **Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease** *Nat Genet* **52**:1169–1177

Krishnan K.C., Kurt Z., Barrere-Cain R., Sabir S., Das A., Floyd R., Vergnes L., Zhao Y., Che N., Charugundla S (2018) **Integration of multi-omics data from mouse diversity panel highlights mitochondrial dysfunction in non-alcoholic fatty liver disease** *Cell systems* **6**:103–115

Kurt Z., Barrere-Cain R., LaGuardia J., Mehrabian M., Pan C., Hui S.T., Norheim F., Zhou Z., Hasin Y., Lusis A.J (2018) **Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease** *Biology of sex differences* **9**:1–14

Langfelder P., Horvath S (2008) **WGCNA: an R package for weighted correlation network analysis** *BMC bioinformatics* **9**



Lonsdale J., Thomas J., Salvatore M., Phillips R., Lo E., Shad S., Hasz R., Walters G., Garcia F., Young N (2013) **The genotype-tissue expression (GTEx) project** *Nature genetics* **45**:580–585

Ma Y., Wang W., Zhang J., Lu Y., Wu W., Yan H., Wang Y (2012) **Hyperlipidemia and atherosclerotic lesion development in Ldlr-deficient mice on a long-term high-fat diet** *PloS one* **7**

Mäkinen V.-P., Civelek M., Meng Q., Zhang B., Zhu J., Levian C., Huan T., Segrè A.V., Ghosh S., Vivar J (2014) **Integrative genomics reveals novel molecular pathways and gene networks for coronary artery disease** *PLoS Genet* **10**

McCarthy M.I., Abecasis G.R., Cardon L.R., Goldstein D.B., Little J., Ioannidis J.P., Hirschhorn J.N (2008) **Genome-wide association studies for complex traits: consensus, uncertainty and challenges** *Nature reviews genetics* **9**:356–369

Mehrabian M., Qiao J.-H., Hyman R., Ruddle D., Loughton C., Lusis A.J (1993) **Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice** *Arteriosclerosis and thrombosis: a journal of vascular biology* **13**:1–10

Momiyama Y., Adachi H., Fairweather D., Ishizaka N., Saita E. (2014) **Inflammation, atherosclerosis and coronary artery disease**

Nikpay M., Goel A., Won H.-H., Hall L.M., Willenborg C., Kanoni S., Saleheen D., Kyriakou T., Nelson C.P., Hopewell J.C (2015) **A comprehensive 1000 Genomes- based genome-wide association meta-analysis of coronary artery disease** *Nature genetics* **47**

Ongen H., Buil A., Brown A.A., Dermitzakis E.T., Delaneau O (2016) **Fast and efficient QTL mapper for thousands of molecular phenotypes** *Bioinformatics* **32**:1479–1485

Parks B.W., Nam E., Org E., Kostem E., Norheim F., Hui S.T., Pan C., Civelek M., Rau C.D., Bennett B.J (2013) **Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice** *Cell metabolism* **17**:141–152

Parks B.W., Sallam T., Mehrabian M., Psychogios N., Hui S.T., Norheim F., Castellani L.W., Rau C.D., Pan C., Phun J (2015) **Genetic architecture of insulin resistance in the mouse** *Cell metabolism* **21**:334–347

Sen S.K., Barb J.J., Cherukuri P.F., Accame D.S., Elkahouloun A.G., Singh L.N., Lee-Lin S.-Q., Kolodgie F.D., Cheng Q., Zhao X (2014) **Identification of candidate genes involved in coronary artery calcification by transcriptome sequencing of cell lines** *BMC genomics* **15**

Shabalin A.A (2012) **Matrix eQTL: ultra fast eQTL analysis via large matrix operations** *Bioinformatics* **28**:1353–1358

Shih D.M., Xia Y.-R., Wang X.-P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K.F., Berliner J.A., Witztum J.L (2000) **Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis** *Journal of Biological Chemistry* **275**:17527–17535

Shu L., Zhao Y., Kurt Z., Byars S.G., Tukiainen T., Kettunen J., Orozco L.D., Pellegrini M., Lusis A.J., Ripatti S (2016) **Mergeomics: multidimensional data integration to identify pathogenic perturbations to biological systems** *BMC genomics* **17**

- Song W.-M., Zhang B (2015) **Multiscale embedded gene co-expression network analysis** *PLoS computational biology* **11**
- Stoeger T., Gerlach M., Morimoto R.I., Nunes Amaral L.A (2018) **Large-scale investigation of the reasons why potentially important genes are ignored** *PLoS biology* **16**
- Storey J.D., Tibshirani R (2003) **Statistical significance for genomewide studies** *Proceedings of the National Academy of Sciences* **100**:9440–9445
- Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S (2005) **Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles** *Proceedings of the National Academy of Sciences* **102**:15545–15550
- Tcheandjieu C., Zhu X., Hilliard A.T., Clarke S.L., Napolioni V., Ma S., Lee K.M., Fang H., Chen F., Lu Y., et al. (2022) **Large-scale genome-wide association study of coronary artery disease in genetically diverse populations** *Nat Med* **28**:1679–1692
- Tsao C.W., Aday A.W., Almarzooq Z.I., Alonso A., Beaton A.Z., Bittencourt M.S., Boehme A.K., Buxton A.E., Carson A.P., Commodore-Mensah Y., et al. (2022) **Circulation** :e153–e639
- Van den Maagdenberg A., Hofker M., Krimpenfort P., De Bruijn I., Van Vlijmen B., Van der Boom H., Havekes L., Frants R. (1993) **Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia** *Journal of Biological Chemistry* **268**:10540–10545
- Vandamme T.F (2014) **Use of rodents as models of human diseases** *Journal of pharmacy & bioallied sciences* **6**
- Von Scheidt M., Zhao Y., Kurt Z., Pan C., Zeng L., Yang X., Schunkert H., Lusis A.J. (2017) **Applications and limitations of mouse models for understanding human atherosclerosis** *Cell metabolism* **25**:248–261
- Wang L., Hauser E.R., Crosslin D., Nelson S., Hale A., Gregory S., Shah S.H., Kraus W.E., Goldschmidt-Clermont P.J., Vance J.M. (2007) **A Multi-Stage Evaluation of Genetic Association with Early-Onset Coronary Artery Disease in MYLK Gene**
- Wang Z.Y., Keogh A., Waldt A., Cuttat R., Neri M., Zhu S., Schuierer S., Ruchti A., Crochemore C., Knehr J., et al. (2021) **Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis** *Sci Rep* **11**
- Wirka R.C., Wagh D., Paik D.T., Pjanic M., Nguyen T., Miller C.L., Kundu R., Nagao M., Coller J., Koyano T.K., et al. (2019) **Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis** *Nat Med* **25**:1280–1289
- Wu J.-X., He K.-Y., Zhang Z.-Z., Qu Y.-L., Su X.-B., Shi Y., Wang N., Wang L., Han Z.-G (2021) **LZP is required for hepatic triacylglycerol transportation through maintaining apolipoprotein B stability** *PLOS Genetics* **17**
- Xiangdong L., Yuanwu L., Hua Z., Liming R., Qiuyan L., Ning L (2011) **Animal models for the atherosclerosis research: a review** *Protein & cell* **2**:189–201

- Yang H., Ding Y., Hutchins L.N., Szatkiewicz J., Bell T.A., Paigen B.J., Graber J.H., de Villena F.P.-M., Churchill G.A. (2009) **A customized and versatile high-density genotyping array for the mouse** *Nature methods* **6**:663–666
- Yeo I.K., Johnson R.A (2000) **A new family of power transformations to improve normality or symmetry** *Biometrika* **87**:954–959
- Yu N., Erb L., Shivaji R., Weisman G.A., Seye C.I (2008) **Binding of the P2Y2 nucleotide receptor to filamin A regulates migration of vascular smooth muscle cells** *Circ Res* **102**:581–588
- Yuan S.-M (2015)  **$\alpha$ -Smooth muscle actin and ACTA2 gene expressions in vasculopathies** *Brazilian journal of cardiovascular surgery* **30**:644–649
- Zhao Y., Blencowe M., Shi X., Shu L., Levian C., Ahn I.S., Kim S.K., Huan T., Levy D., Yang X (2019) **Integrative genomics analysis unravels tissue-specific pathways, networks, and key regulators of blood pressure regulation** *Frontiers in cardiovascular medicine* **6**
- Zhao Y., Chen J., Freudenberg J.M., Meng Q., Consortium C., Rajpal D.K., Yang X. (2016) **Network-based identification and prioritization of key regulators of coronary artery disease loci** *Arteriosclerosis, thrombosis, and vascular biology* **36**:928–941
- Zhao Y., Jhamb D., Shu L., Arneson D., Rajpal D.K., Yang X. (2019) **Multi-omics integration reveals molecular networks and regulators of psoriasis** *BMC systems biology* **13**
- Zhenyukh O., González-Amor M., Rodrigues-Diez R.R., Esteban V., Ruiz-Ortega M., Salices M., Mas S., Briones A.M., Egido J (2018) **Branched-chain amino acids promote endothelial dysfunction through increased reactive oxygen species generation and inflammation** *J Cell Mol Med* **22**:4948–4962
- Zhu J., Sova P., Xu Q., Dombek K.M., Xu E.Y., Vu H., Tu Z., Brem R.B., Bumgarner R.E., Schadt E.E (2012) **Stitching together multiple data dimensions reveals interacting metabolomic and transcriptomic networks that modulate cell regulation** *PLoS Biol* **10**
- Zhu J., Wiener M.C., Zhang C., Fridman A., Minch E., Lum P.Y., Sachs J.R., Schadt E.E (2007) **Increasing the power to detect causal associations by combining genotypic and expression data in segregating populations** *PLoS Comput Biol* **3**
- Zhu J., Zhang B., Smith E.N., Drees B., Brem R.B., Kruglyak L., Bumgarner R.E., Schadt E.E (2008) **Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks** *Nature genetics* **40**:854–861

## Article and author information

### Zeyneb Kurt

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA, Department of Computer and Information Sciences, University of Northumbria, Ellison Pl, Newcastle upon Tyne NE1 8ST, UK

**Jenny Cheng**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA, Interdepartmental Program of Molecular, Cellular and Integrative Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**Caden N. McQuillen**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**Zara Saleem**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**Neil Hsu**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**Nuoya Jiang**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**Rio Barrere-Cain**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**Calvin Pan**

Department of Medicine, Division of Cardiology, University of California, Los Angeles, 650 Charles E Young Drive South, Los Angeles, CA 90095-1679, USA

**Oscar Franzen**

Department of Genetics & Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, US

**Simon Koplev**

Department of Genetics & Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, US

**Susanna Wang**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**Johan Bjorkegren**

Department of Genetics & Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, US, Department of Medicine, (Huddinge), Karolinska Institutet, 141 57 Huddinge, Sweden

### **Aldons J. Lulis**

Department of Medicine, Division of Cardiology, University of California, Los Angeles, 650 Charles E Young Drive South, Los Angeles, CA 90095-1679, USA, Departments of Human Genetics & Microbiology, Immunology, and Molecular Genetics, UCLA, CA 90095, USA, Cardiovascular Research Laboratory, David Geffen School of Medicine, UCLA, CA 90095

### **Montgomery Blencowe**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA, Interdepartmental Program of Molecular, Cellular and Integrative Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**For correspondence:** [montyblencowe@ucla.edu](mailto:montyblencowe@ucla.edu)

ORCID iD: [0000-0001-7147-1895](https://orcid.org/0000-0001-7147-1895)

### **Xia Yang**

Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA, Interdepartmental Program of Molecular, Cellular and Integrative Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA, Interdepartmental Program of Bioinformatics, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

**For correspondence:** [xyang123@ucla.edu](mailto:xyang123@ucla.edu)

## **Copyright**

© 2023, Kurt et al.

This article is distributed under the terms of the [Creative Commons Attribution License \(https://creativecommons.org/licenses/by/4.0/\)](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

## **Editors**

Reviewing Editor

### **Arya Mani**

Yale University School of Medicine, United States of America

Senior Editor

### **David James**

University of Sydney, Australia

## **Reviewer #1 (Public Review):**

This manuscript represents an elegant bioinformatics approach to addressing causal pathways in vascular and liver tissue related to atherosclerosis/coronary artery disease, including those shared by humans and mice and those that are specific to only one of these species. The authors constructed co-expression networks using bulk transcriptome data from human (aorta, coronary) and mouse (aorta) vascular and liver tissue. They mapped human CAD GWAS data onto these modules, mapped GWAS SNPs to putatively causal genes, identified pathways and modules enriched in CAD GWAS hits, assessed those shared between vascular and liver tissues and between humans and mice, determined key driver genes in

CAD-associated supersets, and used mouse single-cell transcriptome data to infer the roles of specific vascular and liver cell types. The overall approach used by the authors is rigorous and provides new insights into potentially causal pathways in vascular tissue and liver involved in atherosclerosis/CAD that are shared between humans and mice as well as those that are species-specific. This approach could be applied to a variety of other common complex conditions.

## Reviewer #2 (Public Review):

### Summary:

Mouse models are widely used to determine key molecular mechanisms of atherosclerosis, the underlying pathology that leads to coronary artery disease. The authors use various systems biology approaches, namely co-expression and Bayesian Network analysis, as well as key driver analysis, to identify co-regulated genes and pathways involved in human and mouse atherosclerosis in artery and liver tissues. They identify species-specific and tissue-specific pathways enriched for the genetic association signals obtained in genome-wide association studies of human and mouse cohorts.

### Strengths:

The manuscript is well executed with appropriate analysis methods. It also provides a compelling series of results regarding mouse and human atherosclerosis.

## Author Response

The following is the authors' response to the original reviews.

### **Reviewer #1 (Public Review):**

*This manuscript represents an elegant bioinformatics approach to addressing causal pathways in vascular and liver tissue related to atherosclerosis/coronary artery disease, including those shared by humans and mice and those that are specific to only one of these species. The authors constructed co-expression networks using bulk transcriptome data from human (aorta, coronary) and mouse (aorta) vascular and liver tissue. They mapped human CAD GWAS data onto these modules, mapped GWAS SNPs to putatively causal genes, identified pathways and modules enriched in CAD GWAS hits, assessed those shared between vascular and liver tissues and between humans and mice, determined key driver genes in CAD-associated supersets, and used mouse single-cell transcriptome data to infer the roles of specific vascular and liver cell types. The overall approach used by the authors is rigorous and provides new insights into potentially causal pathways in vascular tissue and liver involved in atherosclerosis/CAD that are shared between humans and mice as well as those that are species-specific. This approach could be applied to a variety of other common complex conditions.*

*The conclusions are largely supported by the analyses. Some specific comments:*

- 1. It appears that GWAS SNPs were mapped to genes solely through the use of eQTLs. Current methods involve a number of other complementary approaches to map GWAS SNPs to effector genes/transcripts and there is the thought that eQTLs may not necessarily be the best way to map causal genes.*

We agree with the reviewer that multiple approaches can be used to map GWAS SNPs to genes, and eQTLs is only one way to do so. We focused on eQTLs mainly because we aim to address tissue-specificity of eQTLs and the relative higher abundance of eQTLs compared to

other tissue-specific functional genomics data, such as pQTLs and epiQTLs. We now acknowledge this limitation in the discussion section in our revised manuscript and point to future studies utilizing other approaches to map GWAS signals to downstream effectors.

*1. Given the critical causal role of circulating apoB lipoproteins in atherosclerosis in both mice and humans and the central role of the liver in regulating their levels, perhaps the authors could use the 'metabolism of lipids and lipoproteins' network in Fig 3B as a kind of 'positive control' to illustrate the overlap between mice and humans and the driver genes for this network.*

We appreciate the reviewer's excellent suggestion and now elaborate the findings in Fig 3B as a positive control in the results section.

*1. Is it possible to infer the directionality of effect of key driver genes and pathways from these analyses? For example, ACADM was found to be a KD gene for a human-specific liver CAD superset pathway involving BCAA degradation. Are the authors able to determine or predict the effect of genetically increased expression of ACADM on BCAA metabolism and on CAD? Or the directionality of the effect of the hepatic KD gene OIT3 on hepatic and plasma lipids and atherosclerosis.*

The Bayesian networks only have information on which genes likely regulate the others but not the up or down-regulation direction, and the network key driver analysis only considers the enrichment of GWAS candidate genes in the neighborhood of each key driver. Therefore, it is not possible to directly infer whether increasing or decreasing a key driver will lead to up or downregulation of the downstream pathways based on our current analysis. We could, however, examine correlations of key driver genes with downstream genes, or disease traits in relevant datasets. For instance, we checked the mouse atherosclerosis HMDP datasets for the correlations between select key drivers and clinical traits and found various key drivers shared and species-specific in aorta and liver significantly correlate with aortic lesion area and other traits of interest such as LDL levels, and inflammatory cytokines. We have added these new findings into the results section and supplemental tables.

*1. While likely beyond the scope of this manuscript, the substantial amount of publicly available plasma proteomic and metabolomic data could be incorporated into this multiomic bioinformatic analysis. Many of the pathways involve secreted proteins or metabolites that would further inform the biology and the understanding of how these pathways relate to atherosclerosis.*

We appreciate the reviewer's valuable suggestion. Here we focused on liver and aorta gene regulatory networks to understand the tissue-specific mechanisms at the gene level. Indeed, plasma proteomic and metabolomic data could be further incorporated in future studies to understand the pathways captured in the circulation that can capture cross-tissue interactions mediated by secreted proteins and metabolites from different tissues. We have addressed this as a future direction in the discussion section.

*The findings here will motivate the community of atherosclerosis investigators to pursue additional potential causal genes and pathways through computational and experimental approaches. It will also influence the approach around the use of the mouse model to test specific pathways and therapeutic approaches in atherosclerosis. In addition, the computational approach is robust and could (and likely will) be applied to a variety of other common complex conditions.*

## **Reviewer #2 (Public Review):**

### *Summary:*

*Mouse models are widely used to determine key molecular mechanisms of atherosclerosis, the underlying pathology that leads to coronary artery disease. The authors use various systems biology approaches, namely co-expression and Bayesian Network analysis, as well as key driver analysis, to identify co-regulated genes and pathways involved in human and mouse atherosclerosis in artery and liver tissues. They identify species-specific and tissue-specific pathways enriched for the genetic association signals obtained in genome-wide association studies of human and mouse cohorts.*

### *Strengths:*

*The manuscript is well executed with appropriate analysis methods. It also provides a compelling series of results regarding mouse and human atherosclerosis.*

### *Weaknesses:*

*The manuscript has several weaknesses that should be acknowledged in the discussion. First, there are numerous models of mouse atherosclerosis; however, the HMDP atherosclerosis study uses only one model of mouse atherosclerosis, namely hyperlipidemic mice, due to the transgenic expression of human apolipoprotein ELeiden (APOE-Leiden) and human cholesteryl ester transfer protein (CETP). Therefore, when drawing general conclusions about mouse pathways not being identified in humans, caution is warranted. Other models of mouse atherosclerosis may be able to capture different aspects of human atherosclerosis.*

We appreciate the reviewer's valuable insight! Indeed, the specific HMDP atherosclerosis model may miss important mouse pathways that could have overlapped with the human pathways. We have added this important point to the limitations section under the discussion to caution the interpretation of the human-specific pathways, as they could be present in mice but are missed by the specific HMDP atherosclerosis dataset used.

*Second, the mouse aorta tissue is atherosclerotic, whereas the atherosclerosis status of the GTEx aorta tissues is not known. Therefore, it is possible that some of the human or mouse-specific gene modules/pathways may be due to the difference in the disease status of the tissues from which the gene expression is obtained.*

We agree with the reviewer that GTEx vascular tissues have unclear atherosclerosis status. However, in addition to GTEx, we also included the human STARNET dataset which contains vascular tissues from human patients with CAD. Therefore, we believe the comparability of the human and mouse vascular tissue datasets is reasonable.

*Third, it is unclear how the sex of the mice (all female in the HMDP atherosclerosis study and all male in the baseline HMDP study) and the sex of the human donors affected the results. Did the authors regress out the influence of sex on gene expression in the human data before performing the co-expression and preservation studies? If not, this should be acknowledged.*

We acknowledge that the effect of sex in the mouse and human datasets were not regressed out in our analysis. We have added this under the limitations section.

*Fourth, some of the results are unexpected, and these should be discussed. For example, the authors identify that the leukocyte transendothelial migration pathway and PDGF signaling pathway are human-specific in their vascular tissue analysis. These pathways*



*have been extensively described in mouse studies. Why do the authors think they identified these pathways as human-specific? Similarly, the authors identified gluconeogenesis and branched-chain amino acid catabolism as human and mouse shared modules in the vascular tissue. Is there evidence of the involvement of these pathways in atherosclerosis in vascular cells?*

We agree with the reviewer that these unexpected findings warrant further discussion. As pointed out by this reviewer, it is possible that the mouse HMDP atherosclerosis dataset cannot fully represent all mouse atherosclerosis biology and therefore missed the leukocyte migration and PDGF pathways that were identified in the human datasets. Regarding the surprising findings of pathways such as BCAA catabolism in vascular tissues, we acknowledge that future studies will need to further investigate such pathway predictions but also highlight that these pathway terms have many shared genes with more commonly known pathways such as the TCA cycle, which may indicate the involvement of energy metabolism in vascular tissues in CAD development. We have added these points to the discussion section under limitations and concluding remarks.

*Overall, acknowledging these drawbacks and adding points to the discussion will strengthen the manuscript.*

### **Reviewer #1 (Recommendations For The Authors):**

1. *Could the authors comment on why MEGENA produces so many more co-expression modules per tissue than WGCNA?*

As described in the methods section, MEGENA uses a multi-scale clustering structure to generate network modules at different scales, with each scale representing a different compactness level of the modules. At lower compactness scales larger modules are generated; at higher compactness scales, smaller modules are generated. By using all modules obtained from different scales, the total number of modules is much larger than WGCNA which only generates a network at one scale.

1. *Much of the results section involves repeating in the text lists of pathways, modules, and genes that are also listed in Figures 2 and 3. The text in this part of the results could be used more productively to focus on illustrative examples or potential new biology.*

We have revised the results section to reduce repeating long lists of pathways, modules, and genes as suggested.

### **Reviewer #2 (Recommendations For The Authors):**

*In addition to the weaknesses I mentioned in the public review comments, there are a few minor issues that I outline below:*

1. *The authors should introduce atherosclerosis as the underlying cause of CAD in the Introduction. In fact, I believe there are many places in the manuscript where the authors mean atherosclerosis instead of coronary artery disease, especially when presenting and discussing mouse results since the HMDP study did not examine the coronary arteries of mice. I believe the authors should make the appropriate changes throughout the manuscript.*

We have made the changes as suggested.

1. The authors state in the introduction, "For example, mice tend to develop atherosclerotic lesions in the aorta and carotids, while humans often develop lesions in coronary arteries (Ma et al., 2012)." This is not entirely correct, so this sentence should be revised. Several models of mice show coronary artery atherosclerosis development, but most researchers study lesions in larger aortas. Further, humans develop lesions throughout the arterial tree, but perhaps what the authors meant was the most consequential plaque development is in the coronary arteries. Please rephrase.

We have rephrased the statement as suggested.

1. Last line of page 5 should read "...which will drive modules and pathways that are more likely..." not "derive"

Typo corrected.